Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer

J Surg Oncol. 2000 Jul;74(3):223-6. doi: 10.1002/1096-9098(200007)74:3<223::aid-jso14>3.0.co;2-q.

Abstract

Background and objectives: In ovarian cancer, development of safe and effective methods for providing long-term access to the peritoneal cavity has become increasingly important.

Methods: A modified Port-A-Cath (Celsite-port and catheters, B. Braun, Chasseneuil, France) was used in 56 patients with presumed epithelial ovarian cancer at the conclusion of primary or second-look laparotomy. In 37 patients, ports were located on the right costal margin in the midclavicular region and in 19 in the xiphoid region.

Results: In 56 catheters, 8 (13.8%) complications of severe or moderate degree during the treatment were registered. In-flow obstruction of device occurred in 6 patients, and there was 1 viscous perforation and 1 catheter related infectious peritonitis. Grade III-IV pain and in-flow obstruction were developed in the patients with ports implanted on the right costal margin but not with ports implanted in the xiphoid region.

Conclusion: The complication rate of intraperitoneal access devices is comparatively low.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Catheters, Indwelling* / adverse effects
  • Cisplatin / administration & dosage
  • Female
  • Humans
  • Infusions, Parenteral / instrumentation*
  • Infusions, Parenteral / methods
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / surgery

Substances

  • Mitoxantrone
  • Cisplatin